Supplemental material - U Okata-Karigane et al., 2022

Supplemental Material related to "Phase 2 randomized controlled trial of serlopitant, a neurokinin 1 receptor antagonist for chronic pruritus in epidermolysis bullosa. U Okata-Karigane et al., 2022"
Supplemental Figure S1. Participant flow
Supplemental Figure S2. Weekly mean NRS scores stratified by treatment groups for Worst Itch NRS
Supplemental Table S1. Additional eligible criteria
Supplemental Table S2. Minimal Clinically Important Difference (MCID) for the Average Itch NRS at month2
Supplemental Table S3. The change in the static participant assessment of itch on a 5-point categorical scale at month 2

关于《神经激肽1受体拮抗剂塞洛匹坦治疗表皮剥脱性皮炎慢性瘙痒的二期随机对照试验补充材料。U Okata-Karigane 等人，2022》的补充材料：补充图 S1. 参与者流程；补充图 S2. 按治疗分组划分的每周平均NRS评分，针对最严重瘙痒的NRS评分；补充表 S1. 其他合格标准；补充表 S2. 2个月时平均瘙痒NRS评分的最小临床重要差异（MCID）；补充表 S3. 2个月时对瘙痒静态评估在5点分类量表上的变化。